GRF-1 Activators
GRF-1 Activators comprise a diverse array of chemical compounds that indirectly promote the functional activity of GRF-1 through their influence on cellular signaling pathways and cytoskeletal dynamics. Forskolin, by raising intracellular cAMP levels, activates PKA, which then can phosphorylate targets that play roles in cell motility and structure, thereby enhancing GRF-1 role in cytoskeletal rearrangements. Similarly, agents like Y-27632 and GSK269962A, both ROCK inhibitors, foster an environment conducive to cell spreading and actin cytoskeleton reorganization, processes in which GRF-1 is a critical regulator. By inhibiting myosin II ATPase activity, Blebbistatin modulates myosin II-mediated contractility, affecting the cellular architecture and potentially necessitating increased GRF-1 activity to maintain cytoskeletal integrity.
Furthermore, molecules such as PD98059 and ML141 modulate the MAPK/ERK pathway and Cdc42 activity, respectively, challenging the cellular equilibrium and possibly augmenting GRF-1's activity to compensate for these changes. This modulation is complemented by calpain inhibitors like Calpeptin, which stabilize proteins within the cytoskeleton, potentially enhancing the regulatory role of GRF-1 in actin dynamics. Compounds such as Jasplakinolide and Latrunculin A directly affect actin polymerization and stability, requiring active rearrangement of the cytoskeleton, a process where GRF-1 likely plays a pivotal role in facilitating dynamic cellular responses.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly elevates intracellular cAMP levels, which in turn can activate downstream effectors such as PKA. Activation of PKA has been shown to regulate the actin cytoskeleton, which is relevant to GRF-1's role as a GTPase activator for the Rho family, thus enhancing GRF-1 activity in cellular signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK, a downstream effector of RhoA. Inhibition of ROCK leads to reduced stress fiber formation and cellular contraction, which can shift the balance towards cellular processes that require active GRF-1-mediated GTPase activity for RhoA regulation. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Phorbol 12-myristate 13-acetate (PMA) activates Protein Kinase C (PKC), which then can phosphorylate substrates that influence the actin cytoskeleton dynamics. PKC activation can synergize with GRF-1's role in modulating the Rho GTPases, thereby enhancing GRF-1's regulatory function on the cytoskeleton. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that indirectly influences the MAPK/ERK pathway. By inhibiting MEK, PD98059 could lead to alterations in the signaling dynamics, such as reducing negative feedback loops, which could enhance the pathways in which GRF-1 is involved, particularly those associated with cytoskeletal regulation. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 inhibits Rac1 activation by blocking its interaction with guanine nucleotide exchange factors (GEFs), which could shift the balance of Rho GTPase activity towards RhoA and Cdc42, processes in which GRF-1 is directly involved, thus potentially enhancing GRF-1's activity in promoting actin assembly. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 GTPase inhibitor that may indirectly enhance GRF-1 activity by increasing the requirement for GRF-1's GTPase activating function in the presence of decreased Cdc42 activity, thus promoting actin polymerization processes regulated by GRF-1. | ||||||
GSK 269962 | 850664-21-0 | sc-363279 sc-363279A | 10 mg 50 mg | $300.00 $1000.00 | 1 | |
GSK269962A is an inhibitor of ROCK, like Y-27632, and it enhances the cellular processes that are negatively regulated by ROCK. This can lead to increased activity of GRF-1 in regulating the actin cytoskeleton through its GTPase activating function. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpeptin is a calpain inhibitor that can stabilize cytoskeletal proteins by preventing their degradation. This stabilization could increase the need for GRF-1-mediated regulation of the actin cytoskeleton, enhancing its activity indirectly. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and can lead to an increase in nucleation and polymerization, which may enhance GRF-1 activity since GRF-1 can regulate actin dynamics as part of its GTPase activating function for the Rho family. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin is an inhibitor of myosin II ATPase activity, leading to a reduction in myosin II-mediated contractility. This can alter actin dynamics in a way that may require enhanced GRF-1 activity for cytoskeletal reorganization. | ||||||